Please upgrade your browser.
The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the National Clinical Trial Network (NCTN) designed to a
The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the National Clinical Trial Network (NCTN) designed to address important challenges in clinical trials—accelerating recruitment and diversity. The relationship allows NCTN to deliver a platform that provides a comprehensive database of clinical trial options to providers.
KCA and CCF partner on cancer research projects for a sixth year.
The association of autosomal dominant polycystic kidney disease with renal cell carcinoma is infrequent. A case of bilateral renal cell carcinoma in conjunction with autosomal dominant polycystic kidney disease is presented. The discussion emphasizes pertinent diagnostic and therapeutic considerations.
A review of kidney and prostate cancer abstracts from GU ASCO 2013, Orlando, Florida
Prescribing Oral Anticancer Agents: Food-Induced Injury is Preventable
In a stunning example of when treatment might be worse than the disease, a large review of Medicare records finds that older people with small kidney tumors were much less likely to die over the next five years if doctors monitored them instead of operating right away.
Final overall survival results from the phase III study of Aveo Pharmaceuticals' (AVEO_) kidney cancer drug tivozanib were released Tuesday night, and as expected, tivozanib-treated patients were at a greater risk of death than those treated with Onyx Pharmaceuticals' (ONXX_) Nexavar.
Join us March 14 for a day-long live web chat with our members in 102 nations. Celebrate World Kidney Day with your friends from the Kidney Cancer Association.
The University of North Carolina will be hosting its first conference for kidney cancer patients and their families on Saturday, February 23, 2013
The anticancer drug Sutent (sunitinib) does not cause tumors to grow faster after treatment ends, according to a new study.
|Powered by NeonCRM|